SARS-CoV-2 ORF7a Antibody [Janelia Fluor® 525]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11936JF525
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
SARS-CoV-2
Predicted:
Bat-CoV (100%), SARS-CoV (90%). Backed by our 100% Guarantee.
Applications
ELISA
Label
Janelia Fluor 525
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Antibody was raised against a peptide corresponding to 9 amino acids near the carboxyl terminus of SARS-CoV-2 ORF7a protein. The immunogen is located within the last 50 amino acids of the SARS-CoV-2 ORF7a protein.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for SARS-CoV-2 ORF7a Antibody [Janelia Fluor® 525]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Peptide affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SARS-CoV-2 ORF7a
Similar to its role in SARS-CoV, ORF7a of SARS-CoV-2 is an inhibitor of the host tetherin bone marrow stromal antigen-2 (BST-2) (2, 4). Functionally, ORF7a binds to BST-2, inhibiting its viral restriction activity by blocking glycosylation (2, 4).
References
1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1
2. UniProt (P0DTC7)
3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4
4. Taylor, J. K., Coleman, C. M., Postel, S., Sisk, J. M., Bernbaum, J. G., Venkataraman, T., Sundberg, E. J., & Frieman, M. B. (2015). Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. Journal of virology. https://doi.org/10.1128/JVI.02274-15
5. Nelson, C. A., Pekosz, A., Lee, C. A., Diamond, M. S., & Fremont, D. H. (2005). Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure (London, England : 1993). https://doi.org/10.1016/j.str.2004.10.010
Alternate Names
2019-nCoV ORF7a, 2019-nCoV ORF7a Protein, Accessory Protein 7a, COVID-19 Accessory Protein 7a, COVID-19 ORF7a, COVID-19 Protein U122, COVID-19 Protein X4, Human coronavirus ORF7a Protein, ORF7a Protein, Protein U122, Protein X4, SARS-CoV-2 Accessory Protein 7a, SARS-CoV-2 Protein U122, SARS-CoV-2 Protein X4
Gene Symbol
ORF7a
Additional SARS-CoV-2 ORF7a Products
Product Documents for SARS-CoV-2 ORF7a Antibody [Janelia Fluor® 525]
Product Specific Notices for SARS-CoV-2 ORF7a Antibody [Janelia Fluor® 525]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...